ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
July 07, 2021Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X allele. -
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
April 02, 2021Eloxx Pharmaceuticals, Inc. has acquired Zikani Therapeutics, Inc. in an all-stock transaction, combines complementary ribosomal RNA-targeted genetic therapy platforms and therapies for the treatment of rare diseases and oncology. -
Eloxx Pharmaceuticals: Promising Treatment for Rare Genetic Diseases
April 13, 2018The people at Eloxx Pharmaceuticals share a common goal — to bring safe and effective therapies to children and adults suffering from rare genetic diseases as quickly as possible.
Pharma Sources Insight January 2025
